Mei R. Fu, PhD, Offers Strategies to Manage Pain after Breast Cancer Treatment

Video

Dr. Mei R. Fu offers strategies to manage daily or periodic pain after breast cancer treatment and explores the reasons some women may experience it in this recording of her webinar at SHARE, “Persistent and Intermittent Pain After Breast Cancer Treatment.” Watch and listen below. Mei R. Fu, PhD, RN, ACNS-BC, FAAN, is Associate Professor College of Nursing NYU.

Webinar: Persistent and Intermittent Pain after Breast Cancer Treatment from SHARE on Vimeo.

Recent Videos
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Medium closeup shot of a women in front of a dark blue background with graphics that read "All in Against Cancer" and "Ochsner Health"
Smiling woman in front of a blue video call background with logos that say "All in Against Cancer" and "Ochsner Health" above her
woman in front of a dark blue background for Oschner Health
woman in front of a blue background with dark hair
image of a woman in front of a blue background with a navy top
Related Content
Line illustration of an IV drip in gold on a dark blue background

FDA Approves Denosumab Biosimiliars for Prior Authorized Indications

Tim Cortese
March 13th 2025
Article

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Line illustration of a breast with tissue on a cerulean background

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Kyle Doherty
March 5th 2025
Article

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Simple line illustration of breast tissue on a yellow background

PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer

Roman Fabbricatore
February 10th 2025
Article

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.